Research Articles
Off-Target Sequencing Explained: A Complete Guide to Targeted Genomic Safety Assessment in Drug Development
This guide provides researchers, scientists, and drug development professionals with a comprehensive framework for designing and executing targeted off-target sequencing analyses.
Cas Nuclease Showdown: Unprecedented Fidelity Comparison Across Thousands of Genomic Sites Using GenomePAM
This comprehensive analysis provides a systematic, large-scale evaluation of the editing fidelity of key Cas nucleases (including SpCas9, SpCas9-HF1, eSpCas9, xCas9, Cas12a, and hyper-accurate variants) across thousands of diverse genomic...
NAG vs. NGG PAM: A Comprehensive Analysis of Off-Target Effects in CRISPR-Cas9 Editing
This article provides a detailed comparative analysis of off-target editing rates between the canonical NGG Protospacer Adjacent Motif (PAM) and the non-canonical NAG PAM for CRISPR-Cas9 systems.
Choosing the Right Cas Nuclease: A Strategic Guide to PAM Availability for CRISPR Genome Editing
This guide provides a comprehensive, actionable framework for selecting Cas nucleases based on Protospacer Adjacent Motif (PAM) availability in target genomes.
ChIP-seq for dCas9 Binding Sites: A Complete Guide for Epigenetic Researchers and Drug Developers
This comprehensive guide provides researchers, scientists, and drug development professionals with a complete framework for utilizing ChIP-seq to map dCas9 binding sites.
Casgevy vs. Lyfgenia: A Comprehensive Efficacy & Safety Profile Analysis for Sickle Cell Disease Gene Therapies
This article provides a detailed, data-driven comparison of the two recently FDA-approved gene therapies for sickle cell disease (SCD), Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel).
Casgevy (exa-cel) Sickle Cell Disease Clinical Trial Results: A Landmark Analysis for CRISPR Therapeutics
This article provides a comprehensive, technical analysis of the clinical trial results for Casgevy (exagamglogene autotemcel or exa-cel), the first CRISPR/Cas9-based gene-editing therapy approved for sickle cell disease.
Cas9 vs TALEN vs ZFN: A 2024 Comparison of Gene Editing Efficiency, Applications, and Best Practices
This article provides researchers, scientists, and drug development professionals with a comprehensive, current comparison of the three primary programmable nuclease platforms: CRISPR-Cas9, TALENs, and ZFNs.
Cas9 vs Cas12a vs Cas13: A Comprehensive Guide to CRISPR-Cas Specificity, Efficiency & Application Selection
This article provides a detailed comparative analysis of three major CRISPR-Cas systems: Cas9, Cas12a, and Cas13.
Cas9 vs Cas12a: A Structural and Functional Guide for Genome Editing Researchers
This article provides a comprehensive, up-to-date comparison of the two most prominent CRISPR nucleases, Cas9 and Cas12a.